FDA Okays Another Immunotherapy Plus TKI for Advanced RCC FDA Okays Another Immunotherapy Plus TKI for Advanced RCC
The FDA has approved avelumab in combination with the tyrosine kinase inhibitor (TKI) axitinib for the first-line treatment of advanced renal cell carcinoma (RCC).FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Carcinoma | Hematology | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma